Neurogene Inc. (NGNE)
Nasdaq: NGNE · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Who owns Neurogene Inc.
As filed with the SECHolders of 5% or more
9
Prudential Financial, Inc. holds 11.2% of Common, as its SCHEDULE 13G filed Oct 7, 2026 says.
Directors and officers
10
report now, of 44 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 9 named at left.
Holders of 5% or moreshare of the class, as filed
Prudential Financial, Inc.
SCHEDULE 13G · filed Oct 7, 2026 · Common
Jennison Associates LLC
SCHEDULE 13G · filed Oct 6, 2026 · Common Stock
RTW Investments, LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.000001 per share
Redmile Group, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.000001 par value · 9.9% in Feb 17, 2026
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock
Casdin Capital, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.000001 par value
Baker Bros. Advisors LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, par value $0.000001 per share · 9.96% in May 15, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 23, 2025 · Common Stock
Balyasny Asset Management L.P.
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock
Trails Edge Capital Partners, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.000001 par value per share · reported falling below 5%, from 5.1% in Dec 15, 2025
Fmr LLC
SCHEDULE 13G/A · filed May 12, 2025 · COMMON STOCK · reported falling below 5%
Commodore Capital LP
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock, $0.000001 par value · reported falling below 5%
Great Point Partners, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.000001 per share · reported falling below 5%
Janus Henderson Group PLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
What NGNE reports owning in othersstakes of 5% or more, and other ties
Neurogene Inc. reports no stake in another company in the record.
Insider tradesForm 4
17sales
0purchases
17sales on a scheduled plan
4people selling
$1.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 49 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO | 12 | $900,000 | 12 | 0 | $0 |
| Mcminn Rachel | Chief Executive Officer | 1 | $100,000 | 1 | 0 | $0 |
| Cobb Stuart | Chief Scientific Officer | 3 | $100,000 | 3 | 0 | $0 |
| Jordan Julie | Chief Medical Officer | 1 | $0 | 1 | 0 | $0 |